CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GOTTA, A. W.
Right arrow Articles by SULLIVAN, C. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by GOTTA, A. W.
Right arrow Articles by SULLIVAN, C. A.

Canadian Journal of Anesthesia, Vol 17, 527-534, Copyright © 1970 by Canadian Anesthesiologists' Society

A Clinical Evaluation of Pyridostigmin Bromide in The Reversal of Curarization

ALEXANDER W. GOTTA M.D.1 and COLLEEN A. SULLIVAN M.B., CH.B.1

1 Department of Anesthesiology, St. Mary's Hospital, Catholic Medical Center of Brooklyn and Queens, Inc

Pyridostigmin bromide in doses of 10 to 20 mg is an effective antagonist of d-tubocurarine when used in the presence of cyclopropane, diethyl ether, methoxyflurane, nitrous oxide, or halothane. When it is used without concurrent atropine, heavy pharyngeal and tracheal secretions are often found, and vagomimetic cardiac arrhythmias are not uncommon. Protection against secretions and vagal arrhythmias can be obtained only with the simultaneous use of 1.0 mg of atropine sulfate. But, at this dose level, transient tachycardia may occur. Pyridostigmin, as a curare antagonist, is approximately one-half as potent as neostigmine, but it has a longer course of action. A plea is made for adequate reversal of curare or the use of postoperative respiratory assistance in all instances where curare is used.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1970 by the Canadian Anesthesiologists' Society.